vCJD sufferer stable after taking experimental drug
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.A man who contracted variant Creutzfeld-Jakob disease (vCJD), the human form of BSE, has become the first sufferer no longer regarded as terminally ill after taking an experimental drug.
A man who contracted variant Creutzfeld-Jakob disease (vCJD), the human form of BSE, has become the first sufferer no longer regarded as terminally ill after taking an experimental drug.
Jonathan Simms, 20, from Belfast, developed the disease three years ago and was given only months to live. As his health deteriorated, his parents won a legal battle in order to allow him to take the experimental drug pentosan polysulphate.
Mr Simms was the first sufferer to begin taking the drug and is now believed to be the longest-surviving person infected with vCJD.
His father, Don Simms, described how his condition had stabilised after two years of taking the drug. "Jonathan is very stable," Mr Simms told BBC Radio Ulster. "The general consensus is that Jonathan Simms is no longer terminally ill. He is no longer in the last days or weeks of life - we hope they [the doctors] are right."
He said: "There was a 100 per cent certainty that Jonathan would not be here today without some form of treatment." The drug, which has blood-thinning and anti-inflammatory properties, is used to treat cystitis in the US but experts feared that it carried the risk of side-effects.
Dr Stephen Dealler, a consultant in micro-biology at Lancaster Royal Infirmary, said: "Everyone was shocked at how Jonathan responded. His condition seems to have stabilised."
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments